Download PDF
Thromb Haemost 1997; 77(03): 606-608
DOI: 10.1055/s-0038-1656017
Letter to the Editor
Schattauer GmbH Stuttgart

Plasmatic Plasminogen Activator Inhibitor Activity in Patients with Primary Breast Cancer

G-F von Tempelhoff
1   The Dept. of Obstetrics and Gynecology, City Hospital of Ruesselsheim, Germany
,
L Heilmann
1   The Dept. of Obstetrics and Gynecology, City Hospital of Ruesselsheim, Germany
,
M Dietrich
1   The Dept. of Obstetrics and Gynecology, City Hospital of Ruesselsheim, Germany
,
D Schneider
1   The Dept. of Obstetrics and Gynecology, City Hospital of Ruesselsheim, Germany
,
F Niemann
2   Dept. of Behring Diagnostics, Schwalbach, Germany
,
G Hommel
3   Institut for Medical Statistics and Documentation, University of Mainz, Germany
› Author Affiliations
Further Information

Publication History

Received 16 September 1996

Accepted after revision 06 November 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Niwano H, Takahashi H, Taewaki W, Wada K, Seki Y, Shibata A. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Blood Coagulation and Fibrinolysis 1992; 3: 0389-0393
    CrossrefPubMedGoogle Scholar
  • 2 Pappot H, Gardsvoll H, Perdersen AN, Grondahl-Hansen J, Pyke C, Brunner N. Plasminogen Activator Inhibitor 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler 1995; 376: 0259-0269
    PubMedGoogle Scholar
  • 3 de JongE, Knot EAR, Iburg AHC, Rijken DC, Veenhof KHN, Dooijewaard G, ten CasteJW. Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 1987; 57: 0140-0143
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Newland JR, Haire WD. Elevated Plasminogen Activator Inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991; 96: 0602-0604
    CrossrefPubMedGoogle Scholar
  • 5 Rocha E, Páramo JA, Fernández FJ, Cuesta B, Hernández M, Paloma MJ, Rifón J. Clotting activation and impairement of fibrinolysis in malignancy. Thrombosis Research 1989; 54: 0699-0707
    CrossrefPubMedGoogle Scholar
  • 6 von Tempelhoff G-F. Changes of hemorheology and clotting in different gynecologic malignancies. Clin Hemorheology 1995; 54: 0261-0262
    PubMedGoogle Scholar
  • 7 Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer and Metastasis Reviews 1992; 11: 0291-0311
    CrossrefPubMedGoogle Scholar
  • 8 Casslén B, Bossmar T, Lecander I, Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994; 30 A: 1302-1309
    CrossrefPubMedGoogle Scholar